Dermapharm Holding SE, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in the development and production of high-quality generic and specialty pharmaceuticals. Founded in 1991, the company has established a strong presence across Europe, with significant operations in various key markets. The firm is renowned for its innovative approach to drug formulation, focusing on areas such as pain management, oncology, and central nervous system disorders. Dermapharm's commitment to quality and efficiency has positioned it as a trusted partner for healthcare providers and patients alike. With a robust portfolio of products, Dermapharm continues to achieve notable milestones, reinforcing its status as a leader in the pharmaceutical sector.
How does Dermapharm Holding SE's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Dermapharm Holding SE's score of 16 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Dermapharm Holding SE, headquartered in Germany, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As a current subsidiary of Dermapharm Holding SE, any potential emissions data or climate initiatives may be cascaded from the parent company. However, no specific information regarding such data or initiatives has been provided. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate action. While Dermapharm Holding SE has yet to disclose its emissions or commitments, the industry trend indicates a growing emphasis on reducing carbon emissions and enhancing environmental responsibility.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Dermapharm Holding SE has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
